Molecule
Granisetron is a serotonin-3 receptor antagonist indicated for the prevention of nausea and vomiting in adults receiving moderately and/or highly emetogenic chemotherapy regimens of up to 5 consecutive days duration. MedsAcross supplies Granisetron for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
SANCUSO ® is indicated for the prevention of nausea and vomiting in adults receiving moderately and/or highly emetogenic chemotherapy regimens of up to 5 consecutive days duration. SANCUSO is a serotonin-3 (5-HT 3 ) receptor antagonist indicated for the prevention of nausea and vomiting in adults receiving moderately and/or highly emetogenic chemotherapy for up to 5 consecutive days.
Source: US FDA prescribing information
Granisetron is a selective 5-hydroxytryptamine 3 (5-HT 3 ) receptor antagonist with little or no affinity for other serotonin receptors, including 5-HT 1, 5-HT 1A, 5-HT 1B/C, 5-HT 2, for alpha 1 -, alpha 2 -, or beta-adrenoreceptors, for dopamine-D 2, or for histamine-H 1, benzodiazepine, picrotoxin or opioid receptors. Serotonin receptors of the 5-HT 3 type are located peripherally on vagal nerve terminals and centrally in the chemoreceptor trigger zone of the area postrema. During chemotherapy that induces vomiting, mucosal enterochromaffin cells release serotonin, which stimulates 5-HT 3 receptors. This evokes vagal afferent discharge, inducing vomiting. Animal studies demonstrate that, in binding to 5-HT 3 receptors, granisetron blocks serotonin stimulation and subsequent vomiting after emetogenic stimuli such as cisplatin.
Source: US FDA prescribing information
The recommended dosage is a single transdermal system applied to the upper outer arm a minimum of 24 hours, up to a maximum of 48 hours, before chemotherapy. The transdermal system should be worn at minimum, 24 hours after chemotherapy is finished. The transdermal system can be worn for up to 7 days. Application and Removal Instructions Each transdermal system releases 3.1 mg of granisetron per 24 hours for up to 7 days. Each transdermal system is packed in a pouch and should be applied directly after the pouch has been opened. Only wear one transdermal system at any time. Do not cut the transdermal system. Open the pouch and apply the transdermal system to clean, dry, nearly hairless, intact healthy skin on the upper outer arm. Do not place SANCUSO transdermal system on skin that is red, irritated, or damaged.
Source: US FDA prescribing information
SANCUSO is contraindicated in patients with known hypersensitivity to granisetron or to any of the components of the transdermal system. Known hypersensitivity to granisetron or to any of the components of the transdermal system
Source: US FDA prescribing information
Progressive Ileus and Gastric Distention: Granisetron may mask a progressive ileus and/or gastric distention, consider before use in patients with abdominal surgery. Monitor for decreased bowel activity, particularly in patients with risk factors for gastrointestinal obstruction. Serotonin Syndrome: Serotonin syndrome has been reported with 5-HT 3 receptor antagonists alone but particularly with concomitant use of serotonergic drugs. If such symptoms occur, discontinue SANCUSO and initiate supportive treatment. If concomitant use of SANCUSO with other serotonergic drugs is clinically warranted, patients should be aware of a potential increased risk of serotonin syndrome. Skin Reactions: Mild application site reactions have occurred, remove SANCUSO transdermal system if severe reactions or a generalized skin reaction occur.
Source: US FDA prescribing information
The following are serious or otherwise clinically significant adverse reactions reported in other sections of labeling: Progressive ileus and gastric distention Serotonin syndrome Skin reactions Increased drug exposure with use of external heat sources Phototoxicity with ultraviolet light exposure [se Warnings and Precautions ] The most common adverse reaction (≥ 3%) is constipation.
Source: US FDA prescribing information
Serotonergic Drugs Serotonin syndrome (including altered mental status, autonomic instability, and neuromuscular symptoms) has been described following the concomitant use of 5-HT 3 receptor antagonists and other serotonergic drugs, including selective serotonin reuptake inhibitors (SSRIs) and serotonin and noradrenaline reuptake inhibitors (SNRIs). Monitor for the emergence of serotonin syndrome. If symptoms occur, discontinue SANCUSO and initiate supportive treatment.
Source: US FDA prescribing information
Store at 20°-25°C (68°-77°F), excursions permitted between 15°-30°C (59°-86°F). SANCUSO should be stored in the original packaging.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
7 presentations of Granisetron, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Granisetron 1 mg tabletOralGeneric name | — | US FDA | Available on request |
| Granisetron 1 mg/1 mL injectionIntravenousGeneric name | — | US FDA | Available on request |
| Granisetron 4 mg/4 mL injectionIntravenousGeneric name | — | US FDA | Available on request |
| Granisol 2 mg/10 mL oral solutionOral | Intra-Sana Laboratories | US FDA | Available on request |
| Sancuso 3.1 mg/24 hours transdermal patchTransdermal | Cumberland Pharmaceuticals | US FDA | Available on request |
| Granisetron 0.1 mg/mL injectionIntravenousGeneric name | — | US FDA | Available on request |
| Sustol 10 mg/0.4 mL injectionSubcutaneous Cold chain | Heron Therapeutics | US FDA | Available on request |
3 brand names across 1 markets.
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
Yes, on request. MedsAcross lists 7 presentations of Granisetron and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 3 brand names for Granisetron, including Granisol, Sancuso, Sustol.
Yes. The US FDA first approved Granisetron on 29 December 1993, according to Drugs@FDA.
Yes. Granisetron has a central EU marketing authorisation (status: authorised), according to European Medicines Agency data.
At least one listed presentation of Granisetron must be kept cold, so it is shipped in temperature-controlled packaging. Check the storage line on each presentation.
Granisetron is classified under ATC code A04AA02 (Granisetron).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.